Clinical Trial Update: Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating IMA-026 for allergen-induced late asthma response in mild asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• IMA-026

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Asthma | Phase 1 | Status: COMPLETED